Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by mining4dollarson May 16, 2013 5:22pm
147 Views
Post# 21405439

RE: RE: RE: RE: AGM comin up next Friday.. Bet Int

RE: RE: RE: RE: AGM comin up next Friday.. Bet Int

Thanks JD and Minib..both insightful... note, i never said they WOULD, i merely said they COULD.

I've tried to guess management's motivations for doing what they've done thus far and have been wrong.. all i am saying is it is a possibility.  Endpoint data is different than what would be released if they WERE to include any sort of efficacy. 

"Endpoint data"| is the data gained at the end of the 8 month treatment, in addition to the 4 month follow up after treatment is completed.  There would be zero endpoint data at this point; though there would be PLENTY of basic efficacy observations that COULD be included at this point; if again, management CHOSE TO.

either way, all i am saying is it is a possibility and we will all soon find out in 4 trading days from now.

Note, I believe minib you conceded that in fact it was possible for management to release such data if they chose to based on your last post... though if you or anyone else wants further clarifications as to whether it is a possibility i emplore you to simply Google the phrase "Interim phase 2 efficacy" ....; where you will see COUNTLESS other company releases.

 

Bullboard Posts